Media & Coverage

2024

Radioembolization With Imageable Glass Y90 Microspheres for Hepatocellular Carcinoma

Read More»»

Potential of Imageable Glass Y90 Microspheres for Radioembolization Among Patients With Hepatocellular Carcinoma

Read More»»

New investigational Eye90 microspheres® radioembolization therapy treats liver cancer in a first-in-human pilot trial – SIR Today Annual Meeting News

Read More»»

2023

Read More»»

ABK Biomedical to initiate clinical trial using Eye90 microspheres in medical treatment

Read More»»

ABK Biomedical gets FDA IDE approval for Route90 trial of Eye90 therapy

Read more»»

2022

FDA OKs ABK Biomedical’s Embolic Microspheres

Read More»»

A Better See-And-Do Technology

Read More»»

2021

ABK Biomedical begins liver tumour trial with Eye90 microspheres

Read more»»

Corporate Offices

Halifax Office (Main Office)
155 Chain Lake Drive
Unit 32
Halifax, NS B3S 1B3
Canada

T. 902.442.4009

 

Orange County Office
555 Corporate Drive 
Suite 105
Ladera Ranch, CA, 92694
USA

ABK Biomedical Inc. provides and continues to provide accurate information on its website. However, ABK Biomedical Inc. assumes no responsibility for the accuracy and/or completeness, express or implied, as to the information contained or omitted and/or the products described. Furthermore, ABK Biomedical Inc. may change the products mentioned, and their stage in development, at any time without notice. ABK Biomedical Inc. is a clinical-stage company engaged in the research and development of new medical devices. Eye90 microspheres® is considered an investigational product and is NOT FDA-approved for use.

Copyright 2022 - All International Rights Reserved